• Discussions ongoing with substantial securityholder Viburnum Funds regarding proposed secured loan facility
• Exploring alternative funding structures, including a pro rata entitlement offer
• Viburnum indicates willingness to take up full pro rata entitlement and partially underwrite any shortfall

Universal Biosensors, Inc. (ASX: UBI) provides an update regarding its funding strategy and the non-binding term sheet announced on 2 July 2025 with its substantial securityholder, Viburnum Funds Pty Ltd (Viburnum) in respect of a proposed secured loan facility. While discussions regarding the proposed secured loan facility remain ongoing, the Company and Viburnum are continuing to explore alternative funding structures and it is currently expected that the structure of the funding transaction as previously announced will be varied. One such alternative funding structure currently being considered includes a pro rata entitlement offer of new CDIs over new fully paid shares of common stock in the Company to all eligible existing securityholders of the Company (Entitlement Offer). The terms of any Entitlement Offer, including as to timing and pricing, remain subject to ongoing discussion and negotiation. At this stage, no binding commitment has been made by Viburnum in relation to the proposed Entitlement Offer. However, Viburnum has indicated that, subject to certain conditions being satisfied (including the Company continuing to progress the divestment of its healthcare and HRL assets), it would be prepared to take up its full pro rata entitlement and partially underwrite any shortfall under the Entitlement Offer. In light of these developments, the Company advises that the milestone dates in the indicative timetable for the proposed funding transaction as described in its announcement on 2 July 2025 will not be met as originally contemplated. To facilitate the ongoing discussions, Viburnum has agreed to extend the due diligence period under the non-binding term sheet previously announced by one week to Friday, 15 August 2025. The Company will provide a further market update, including a revised indicative timetable, once the terms of the revised funding transaction has been finalised with Viburnum.